Orchard Therapeutics Announces Agreement with the Beneluxa Consortium Enabling Reimbursed Access to Libmeldy
BOSTON and LONDON, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, a global gene therapy leader, today announced the company...
Brain
XVIVO Presents Report on Operations 2023
GOTHENBURG, SWEDEN / ACCESSWIRE / January 25, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)Fourth quarter 2023 (October 1 - December 31)...
ReAlta Life Sciences Strengthens Board of Directors with Appointment of Two Accomplished Biotechnology Innovators
New appointments bring deep research and development expertise and technology innovation to support continued advancement of ReAlta’s EPICC Technology PlatformNORFOLK,...
Annovis Bio Refines Timeline for Parkinson’s Phase III Study Data Announcement
MALVERN, Pa., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel...
ZyVersa Therapeutics Announces Peer-Reviewed Article Supporting the Therapeutic Potential of Targeting ASC Specks During Progression of Alzheimer’s Disease
Research demonstrated that activation of the inflammasome/ASC speck pathway has a vital role in synaptic degeneration in Alzheimer’s Disease (AD).ZyVersa...
Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders
PRESS RELEASE Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted...
Theratechnologies Receives Complete Response Letter (CRL) from the FDA for the F8 Formulation of Tesamorelin sBLA
FDA requesting clarifications around chemistry, manufacturing and controls and additional information related to immunogenicityCRL does not impact commercial availability of...
Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders
PRESS RELEASE Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted...
CORRECTING and REPLACING Nalu Medical, Inc. Presents Long-term and Holistic Outcomes from the COMFORT RCT for PNS at NANS 2024
CARLSBAD, Calif.--(BUSINESS WIRE)--Please replace the release with the following corrected version due to multiple revisions. The updated release reads: NALU...
Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device – the Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) System
HOUSTON, TX, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced...
Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
REDWOOD CITY, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative...
MyndTec Inc. Receives Statement of Claim and Intends to Defend Itself
Mississauga, Ontario--(Newsfile Corp. - January 22, 2024) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the "Company"), a medical technology company,...
Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024...
ORIC Pharmaceuticals Announces $125 Million Private Placement Financing
Funding from new and existing investors including Viking Global Investors, Commodore Capital, Frazier Life Sciences, Venrock Healthcare Capital Partners, New...
RespireRx Pharmaceuticals Inc. Announces the Appointment of Dr. Dariusz Naziek to Its Board of Directors
Glen Rock, N.J., Jan. 22, 2024 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Market:RSPI) (“RespireRx” or the “Company”), a...
Taysha Gene Therapies Announces Poster Presentation on TSHA-102 in Rett Syndrome at Upcoming British Paediatric Neurology Association 2024 Annual Conference
DALLAS, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on...
Bionano Announces the Final Speaker Lineup for 2024 Symposium with 33 OGM Presentations and Live Panel Discussions Across a Wide Range of Research Applications
26 different customers representing North America, Asia and Europe33 oral presentations across four consecutive days69 scientific posters will be featured in a virtual...
ORYZON to Host KOL Event on Phase IIb PORTICO Topline Study Results of Vafidemstat in Borderline Personality Disorder on January 25, 2024
MADRID, Spain and BOSTON, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical...
De Oro Devices Names Cori Lathan, PhD, as New CEO
Dr. Lathan brings two decades of medical technology with her to drive the health tech startup forwardSAN LUIS OBISPO, CA...
Biotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of Directors
Highly accomplished biopharmaceutical industry executive with successful track record in the commercialization and launch of drugs in varied therapeutic areas...